Biodexa Pharmaceuticals Plc (BDRX) stock forecast & analysis
2.40
NasdaqCM · USDDelayed by 15 minutes
Up: +0.04, +1.5%
3 analyses
- Open
- 2.42
- Previous close
- 2.37
- Day range
- 2.36 – 2.42
- 52-week range
- 2.28 – 357.60
- Volume (shares)
- 9.15K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 524.24K
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.27
- Market cap
- 1.26M
Market Scanner’s AI analysis of Biodexa Pharmaceuticals Plc (BDRX), updated October 2026: BDRX's Phase 3 Serenta trial enrollment milestone and accelerated timeline contrasted with persistent unprofitability and a strong bearish technical trend.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Biodexa Pharmaceuticals Plc (BDRX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
BDRX's Phase 3 Serenta trial enrollment milestone and accelerated timeline contrasted with persistent unprofitability and a strong bearish technical trend.
Recent analyses for BDRX covered the company's progress in its Phase 3 Serenta trial for Familial Adenomatous Polyposis (FAP), including reaching a 100-patient enrollment milestone and an accelerated analysis timeline. This clinical development was discussed alongside the company's ongoing financial performance, which has consistently shown negative gross profits and net incomes, and a significant downward trend in its stock price relative to key moving averages.
BDRX news & sentiment
News coverage highlighted positive developments in BDRX's Phase 3 Serenta trial, including reaching a key enrollment milestone and an accelerated analysis timeline. Broader market news noted volatility in European equities traded in the US, but this was not specific to BDRX. No social media discussion was covered in the provided notes.
BDRX technical picture
The stock price has shown a strong downward trend, trading significantly below key moving averages with bearish momentum indicated by MACD readings. Technical indicators presented mixed signals regarding oversold conditions and buying pressure, with the price action generally sitting near the lower Bollinger Band.
Fundamentals
The company has consistently reported negative gross profits and net losses over the past four fiscal years, with negative operating cash flow. As of June 30, 2026, total debt was zero, and the company held $3.23 million in cash, with current and quick ratios indicating sufficient short-term assets.
Factors discussed — upside
- Phase 3 Serenta trial reached 100-patient enrollment milestone.
- Accelerated timeline for key analysis of the Serenta trial.
- Zero total debt reported as of June 30, 2026.
- Current and quick ratios indicate sufficient short-term assets to cover liabilities.
Factors discussed — risks
- Persistent negative gross profits and net incomes from 2022-2025.
- Stock price significantly below 50-day and 200-day simple moving averages.
- Strong downward trend indicated by 30-day and 91-day price changes.
- Negative operating cash flow for the past four fiscal years.
- High volatility indicated by a Beta of 1.283.
- Clinical trial progress
- Financial performance
- Technical indicators
- Biotechnology industry
Summary updated .
BDRX technical indicators
Common technical indicators for BDRX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 4.56 | Price below |
| 10-day exponential moving average | 2.63 | Price below |
| Relative strength index (14-day) | 32.76 | Neutral |
| MACD line (12/26/9) | -0.6482 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 1.89 – 4.17 | Price inside the bands |
BDRX stock forecast — AI outlook
The most recent historical sample analysis of BDRX recorded this AI decision distribution. Get a current verdict.
Buy 10%Hold 20%Sell 70%
As of
Analyses
Historical, AI-generated samples of past BDRX.US analyses — one per day, shown for context, not current guidance. Newer reports are locked; sign in to read them or generate a fresh one.
Bearish
The company reports negative profitability and significant losses over the trailing twelve months and for the fiscal year 2025. While the 7-day stock change is positive, longer-term trends and key moving averages indicate a bearish outlook.
Frequently asked questions
- What is the bull case for Biodexa Pharmaceuticals Plc?
- The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities.
- What are the risks for Biodexa Pharmaceuticals Plc?
- Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted.
- Is Biodexa Pharmaceuticals Plc bullish or bearish?
- Recent AI analyses of Biodexa Pharmaceuticals Plc examined factors on both sides. Discussed upside: The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities. Discussed risks: Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Biodexa Pharmaceuticals Plc?
- News coverage highlighted positive developments in BDRX's Phase 3 Serenta trial, including reaching a key enrollment milestone and an accelerated analysis timeline. Broader market news noted volatility in European equities traded in the US, but this was not specific to BDRX. No social media discussion was covered in the provided notes.
- What is the Biodexa Pharmaceuticals Plc (BDRX) stock forecast?
- Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for Biodexa Pharmaceuticals Plc (BDRX), dated 2026-09-14, recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. It is a dated historical sample shown for context, not current guidance.
- What is the Biodexa Pharmaceuticals Plc (BDRX) stock prediction for 2026?
- Market Scanner does not make price predictions for 2026. As of 2026-09-14, its most recent historical sample analysis of Biodexa Pharmaceuticals Plc (BDRX) recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. Newer analyses are available after sign-in.
- How does Market Scanner analyse Biodexa Pharmaceuticals Plc?
- Every analysis of Biodexa Pharmaceuticals Plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Biodexa Pharmaceuticals Plc?
The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities.
What are the risks for Biodexa Pharmaceuticals Plc?
Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted.
Is Biodexa Pharmaceuticals Plc bullish or bearish?
Recent AI analyses of Biodexa Pharmaceuticals Plc examined factors on both sides. Discussed upside: The bull case for BDRX centers on progress in its Phase 3 Serenta trial, marked by reaching a 100-patient enrollment milestone and an accelerated analysis timeline. Additionally, the company reported zero total debt as of June 30, 2026, and its current and quick ratios indicate sufficient short-term assets to cover liabilities. Discussed risks: Risks for BDRX include persistent negative gross profits and net incomes from 2022 through 2025, alongside negative operating cash flow over the past four fiscal years. The stock's technical indicators show a strong downward trend, with the price significantly below key moving averages and high volatility noted. These are descriptive observations, not a recommendation.
What is the latest sentiment on Biodexa Pharmaceuticals Plc?
News coverage highlighted positive developments in BDRX's Phase 3 Serenta trial, including reaching a key enrollment milestone and an accelerated analysis timeline. Broader market news noted volatility in European equities traded in the US, but this was not specific to BDRX. No social media discussion was covered in the provided notes.
What is the Biodexa Pharmaceuticals Plc (BDRX) stock forecast?
Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for Biodexa Pharmaceuticals Plc (BDRX), dated 2026-09-14, recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. It is a dated historical sample shown for context, not current guidance.
What is the Biodexa Pharmaceuticals Plc (BDRX) stock prediction for 2026?
Market Scanner does not make price predictions for 2026. As of 2026-09-14, its most recent historical sample analysis of Biodexa Pharmaceuticals Plc (BDRX) recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. Newer analyses are available after sign-in.
How does Market Scanner analyse Biodexa Pharmaceuticals Plc?
Every analysis of Biodexa Pharmaceuticals Plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh BDRX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.